Summit Therapeutics sinks 16% after the FDA rejects
Summit Therapeutics' stock fell 16.44% to $11.82 on Nov. 16, 2026, after the FDA rejected ivonescimab due to insufficient survival data. The company reported $613 million in net losses for the first nine months of 2026, with no product revenue. Analysts noted the rejection could impact Summit's larger lung cancer program.
How this was made
The 30-second read
Why it matters
The FDA complete response letter closes the nearest path to a U.S. launch and signals that tumor control without statistically significant overall survival is not enough, potentially affecting both the specific indication and investor expectations for the broader first-line program.
Market read
A same-session regulatory denial drove a large single-day equity repricing, with the market focusing on survival-endpoint gating and implications for future resubmission or first-line development.
What to watch
The article says Summit has not disclosed how the FDA weighed later cuts or other indications, so the market may be missing details that could support a resubmission strategy.
Background
Summit’s ivonescimab application for EGFR-mutated, non-squamous non-small cell lung cancer was reviewed under the HARMONi trial, where progression-free survival was met but overall survival was not statistically significant in the primary analysis.
Ticker impact
Summit Therapeutics shares plunged after the FDA issued a complete response letter rejecting ivonescimab for lung cancer due to lack of statistically significant overall survival.
Likely further downside or high volatility as the market reprices the probability/timing of any U.S. approval and the broader first-line lung cancer program efficacy bar.
The article states the FDA concluded substantial evidence of effectiveness was not established without statistically significant overall survival improvement, and the stock fell about 16% on heavy volume the next session.
Market effects
Raises the bar for oncology immunotherapy/targeted combinations where progression-free survival alone is insufficient for FDA acceptance.
US biotech sentiment likely pressured, with healthcare ETFs and peers down modestly on the same day.
May affect global EGFR-mutated lung cancer development strategies if survival endpoints remain the key gating factor across regions.
Counterpoint
Investors may be over-discounting the FDA’s interpretation, since the article notes later analyses and an Akeso-run China study showed statistically significant overall survival.
Key entities
- companySummit Therapeutics
US-listed biotech whose ivonescimab FDA review resulted in a complete response letter tied to overall survival evidence.
- regulatorFDA
Issued the complete response letter, stating substantial evidence of effectiveness was not established without statistically significant overall survival improvement.
- drugivonescimab
Summit’s only drug in the article, rejected by the FDA for the described lung cancer indication based on survival endpoint requirements.
- clinical_trialHARMONi trial
Trial whose primary overall survival analysis missed statistical significance, driving the FDA’s effectiveness conclusion.



